about
Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse.Investigating the Extremes of Antibiotic Use with an Epidemiologic FrameworkStudent Characteristics Associated with Successful Matching to a PGY1 Residency Program.Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies.High-Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin.Factors contributing to vancomycin-resistant Enterococcus spp. horizontal transmission events: exploration of the role of antibacterial consumption.Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Prediction of inventory sustainability during a drug shortage.Pharmacokinetics of centhaquin citrate in a rat model.Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.A Simple Microsoft Excel Method to Predict Antibiotic Outbreaks and Underutilization.Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing.Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections.Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.Erratum for Rao et al., treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.Engaging Pharmacy Students in Research Through Near-Peer Training.Population pharmacokinetics of polymyxin B in acutely ill adult patients.Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.Resolution of acyclovir-associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature.Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection.Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia.Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics.Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.Impact of vancomycin treatment duration and dose on kidney injury.Analysis of an Infectious Diseases Pharmacist on Call Pager Program to Inform Educational Efforts.Quantifying the Importance of Active Antimicrobial Therapy among Patients with Gram-negative Bloodstream Infections: Cefepime as a Representative AgentMeasuring the impact of varying denominator definitions on standardized antibiotic consumption rates: implications for antimicrobial stewardship programmesCarbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis
P50
Q35960730-D7E36222-6AA4-478A-9C9B-3473F4BBEA67Q36571839-B083A8D2-DF17-4EC3-BD3D-9E8D14097876Q36933322-05B65E5A-CEA3-4BBD-AAB3-6CF116181389Q37078159-112C8835-8EB9-4B03-818D-D6B3458BD1A4Q37287667-12C12713-A6B2-42F7-8FEB-9A439DC2D6D3Q38542796-30E2601C-E46B-4232-8390-7379D0EE8F0BQ38625062-AB975DA0-01E7-495D-95CB-F060CD3FE307Q38627075-46008A91-81FB-41A3-A485-5085392EAC3BQ38662969-C177AB39-88AC-4C5D-BAD5-D4906FE21578Q38697828-FC2EA1A0-288C-45D7-B681-3D036E2E4A60Q38698374-466308A8-B0D3-4617-8D5C-CAD7916A2A66Q38741453-295D7408-DE50-420A-BC8E-4696FABFE763Q38844575-F90B66BE-CE03-4B2D-9A9C-40F97E743DF1Q40149941-2829AC97-038A-4BE8-817A-32986A355820Q40150748-750BDB1A-E1FE-4705-B426-94D999159A1EQ40218376-664725CF-ED4C-4DDC-9B24-5B6A65CA4705Q40300254-5ACC2308-B1BD-46DB-8E8B-98CA4813B52EQ40363114-1FA5B2B2-6E78-455C-9899-E8200CEE1F44Q40553288-6D271F42-4936-4D91-A40B-9B1866AFA7CBQ40586250-0040B867-2AD8-44FE-9986-6BB7576B126FQ41081439-169CFB39-3C29-4E94-A742-C67D673B5811Q41172930-A765E1DC-BCF4-43DE-B318-D661A545B4FDQ41391695-424DDDD1-7FA2-46B4-B549-F7D27C1787DCQ42012688-A6133671-10E8-4651-B7F6-9452FF43EA1BQ43223514-6E1BE315-8086-4018-9A0A-E0E0D2BFA2B8Q46126338-85B65EFD-9A91-406F-9975-4B209C38FD8BQ47149453-0A3EFCC9-0456-4890-9B5B-46CDB422F30AQ47195590-2BBF8DE8-5CBE-4787-9BB1-959AAAC4A18AQ47195600-1372CD1F-C7E7-454D-A38D-5B033D70947DQ47715161-F8E523C1-39DE-43FE-80B2-C281DD1E3ED2Q47904608-B83DE123-4DCE-4F34-AAD3-0DCBC13B8CD9Q49702690-67B6CDFB-5286-4207-82D1-7E86BDD311BCQ52670587-BA995195-870B-4369-B99D-4B03FFE7C637Q53100525-D7C0B66A-D3B7-433B-B72A-105D397D485CQ53187811-81CE1D92-F2EE-4E6F-B09A-691380BA6091Q54374560-04DCBAD2-7169-4DD6-8E23-F28EF40A8202Q55223041-D21AF53B-06B9-4788-B842-C69E1D28C914Q57478199-BFF7AD58-4AF9-44B6-9710-BECEC83F550CQ57779595-7C7F892B-9660-435C-A1CE-8FFF16DC5C29Q57779598-5466B63E-07C7-4E99-BEAB-91B1CCB5A44A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nathaniel J. Rhodes
@ast
Nathaniel J. Rhodes
@en
Nathaniel J. Rhodes
@es
Nathaniel J. Rhodes
@sl
type
label
Nathaniel J. Rhodes
@ast
Nathaniel J. Rhodes
@en
Nathaniel J. Rhodes
@es
Nathaniel J. Rhodes
@sl
prefLabel
Nathaniel J. Rhodes
@ast
Nathaniel J. Rhodes
@en
Nathaniel J. Rhodes
@es
Nathaniel J. Rhodes
@sl
P106
P1153
55975469700
P21
P31
P496
0000-0002-0018-5434